How Biotechs Can De-Risk CNS Clinical Development Through Early Modeling, Simulation and Study Design
Shreya Yeramilli
A guide to accelerating CNS clinical development programs with data-driven insights, targeted populations, and regulator-ready evidence This white paper explores how the early integration of modeling & simulation, as well as strategic study design, can help to de-risk CNS clinical development. CNS programs present a unique set of challenges due to limited biomarker availability, intricate […] The post How Biotechs Can De-Risk CNS Clinical Development Through Early Modeling, Simulation and Study